Get the Stockscreener App
13.81
2.14%
0.29
After Hours:
13.87
0.06
+0.43%
Overview
News
Price History
Option Chain
Why RDY Down?
Discussions
Forecast
Stock Split
Dividend History
Dr Reddys Laboratories Ltd Adr stock is traded at $13.81, with a volume of 1.18M.
It is up +2.14% in the last 24 hours and down -12.09% over the past month.
Dr. Reddy's is one of the largest generic drug manufacturers in the world. It has a significant presence in North America, a region that makes up roughly half of its generics sales, and it services India (about 20% of its generics sales), Russia (10%), and certain European and Latin American countries. Beyond simple generics, Dr. Reddy's also has a solid portfolio of injectables which make up 25% of its North America sales. In branded generic markets like India, Dr. Reddy's has established a compelling presence with its strong brand name and earned a top five spot in key therapeutic areas including oncology and gastroenterology. Dr. Reddy's also has an active pharmaceutical ingredient business that manufactures over 150 APIs and sells in over 75 countries.
See More
Previous Close:
$13.52
Open:
$13.69
24h Volume:
1.18M
Relative Volume:
0.86
Market Cap:
$2.30B
Revenue:
$3.47B
Net Income/Loss:
$668.83M
P/E Ratio:
3.4416
EPS:
4.0127
Net Cash Flow:
$253.46M
1W Performance:
-2.40%
1M Performance:
-12.09%
6M Performance:
-14.36%
1Y Performance:
-0.49%
1-Day Range:
$13.66
$13.83
1-Week Range:
$13.36
$14.20
52-Week Range:
$13.36
$16.89
Dr Reddys Laboratories Ltd Adr Stock (RDY) Company Profile
Compare RDY with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
RDY
Dr Reddys Laboratories Ltd Adr
|
13.81 | 2.30B | 3.47B | 668.83M | 253.46M | 4.0127 |
|
ZTS
Zoetis Inc
|
172.71 | 77.92B | 9.15B | 2.43B | 2.31B | 5.32 |
|
TAK
Takeda Pharmaceutical Co Adr
|
13.70 | 43.43B | 30.27B | 1.93B | 3.45B | 0.6044 |
|
HLN
Haleon Plc Adr
|
9.57 | 43.27B | 14.26B | 1.55B | 0 | 0.3383 |
|
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
17.84 | 20.21B | 16.77B | -959.00M | 1.37B | -0.85 |
|
NBIX
Neurocrine Biosciences Inc
|
153.29 | 15.52B | 2.24B | 385.90M | 440.10M | 3.73 |
Dr Reddys Laboratories Ltd Adr Stock (RDY) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Dec-19-24 | Downgrade | Nomura | Buy → Neutral |
| Jan-11-24 | Downgrade | Jefferies | Buy → Underperform |
| Aug-29-23 | Downgrade | HSBC Securities | Buy → Hold |
| May-18-23 | Downgrade | Bernstein | Outperform → Mkt Perform |
| Mar-17-23 | Upgrade | BofA Securities | Neutral → Buy |
| Jan-30-23 | Initiated | JP Morgan | Underweight |
| Nov-14-22 | Downgrade | Credit Suisse | Neutral → Underperform |
| Jan-03-22 | Resumed | BofA Securities | Neutral |
| Jul-27-21 | Downgrade | Credit Suisse | Outperform → Neutral |
| Feb-02-21 | Upgrade | Barclays | Equal Weight → Overweight |
| Sep-18-20 | Upgrade | BofA Securities | Neutral → Buy |
| Sep-18-20 | Upgrade | Investec | Sell → Hold |
| Jan-28-20 | Downgrade | CLSA | Buy → Outperform |
| Jan-27-20 | Downgrade | CLSA | Buy → Outperform |
| Jan-09-20 | Upgrade | Citigroup | Sell → Buy |
| Nov-04-19 | Downgrade | BofA/Merrill | Buy → Neutral |
| Sep-04-19 | Upgrade | Credit Suisse | Underperform → Outperform |
| Jul-01-19 | Upgrade | Macquarie | Neutral → Outperform |
| Jun-20-19 | Initiated | Deutsche Bank | Hold |
| Jun-11-19 | Initiated | Barclays | Equal Weight |
| May-20-19 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Feb-19-19 | Upgrade | CLSA | Outperform → Buy |
| Jan-17-19 | Downgrade | Citigroup | Neutral → Sell |
| Sep-21-17 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Aug-31-17 | Upgrade | CLSA | Underperform → Outperform |
| Jul-28-17 | Downgrade | CLSA | Underperform → Sell |
| Jul-27-16 | Downgrade | HSBC Securities | Hold → Reduce |
| Jul-27-16 | Downgrade | Jefferies | Hold → Underperform |
| Feb-10-16 | Upgrade | Credit Agricole | Underperform → Buy |
| Nov-10-15 | Downgrade | Citigroup | Buy → Neutral |
View All
Dr Reddys Laboratories Ltd Adr Stock (RDY) Latest News
Asian Equities Traded in the US as ADRs Rise in Tuesday Trading - MSN
Weekly Stock Grader Analysis: Upgrades & Downgrades on Top Blue-Chip Stocks - InvestorPlace
Dr. Reddy’s Labs ADR earnings missed by $0.02, revenue fell short of estimates - Investing.com
Dr Reddy's Laboratories Q3 Earnings: Double-Digit Growth Aided By Newly Acquired Nicotine Replacement Business - Benzinga
Coupang Inc (NYSE: CPNG): A Blank Check? - Stocks Register
Wipro Q3 Results: Large deal wins fall 35% from last quarter, capital allocation policy changed - CNBCTV18
Infosys Q3 Results: FY25 revenue growth guidance revised higher for the third time in a row - CNBCTV18
Dr. Reddy's Laboratories Limited (NYSE:RDY) Shares Sold by JPMorgan Chase & Co. - MarketBeat
Asian Equities Traded in the US as ADRs Rise in Thursday Trading - MSN
Buy Dr Reddy's & IRB Infra shares; sell JSW Energy stock, says YES Securities - Business Today
Asian Equities Traded in the US as American Depositary Receipts Open Week Lower in Monday Trading - MSN
Asian Equities Traded in the US as American Depositary Receipts Edge Higher in Tuesday Trading - MSN
Where is Dr Reddy's Share Price Headed in 2025? - Equitymaster
Weekly Upgrades and Downgrades - InvestorPlace
Stock Market News Today Live Updates on December 20, 2024 : Top Gainers and Losers today on 20 December, 2024: Dr Reddys Laboratories, ICICI Bank, Tech Mahindra, Trent among most active stocks; Check full list here | Stock Market News - Mint
Infosys, Wipro ADRs end with gains of up to 4% post Accenture results, can Indian IT replicate the move? - CNBCTV18
Dr Reddy’s shares jump over 4 per cent on upgrade by NomuraMarket News - The Financial Express
Zopiclone Market Forecast: Trends and Investment - openPR
Dr Reddy's Laboratories Share Price Live Updates: Disclosure Under Regulation 30 Of SEBI (LODR) Regulatio... - The Economic Times
Dr Reddy’s will top up base business with innovation in India: M V Ramana - BusinessLine
ADR, GDR Listings of Indian companies - Goodreturns
Asian Equities Traded in the US as American Depositary Receipts Edge Down in Wednesday Trading - MSN
NVO Stock Quote Price and Forecast - CNN
Dr Reddy's Labs tanks over 3% after USFDA inspects Hyderabad API facility - Business Standard
Stocks to watch on November 21: Adani Group stocks, Dr Reddy's, Godrej Properties, Tata Power, GRSE, UPL, Bharti Airtel - Upstox
Asian Equities Traded in the US as American Depositary Receipts Start Week Lower in Monday Trading - MSN
Dr Reddy's shares fall 3% as pharma major receives 7 observations from USFDA; check details - Upstox
Asian Equities Traded in the US as American Depositary Receipts Flat in Tuesday Trading - MSN
Asian Equities Traded in the US as American Depositary Receipts Decline in Wednesday Trading - MSN
Jharkhand Elections Phase 2: Richest candidate declares assets worth Rs 402 cr – Check list of top 10 wealthiest candidates - The Financial Express
Jharkhand Phase 2 Elections 2024: 122 candidates with serious criminal cases get tickets, shows ADR report - The Financial Express
Dr. Reddy's Laboratories Limited Just Missed EPS By 12%: Here's What Analysts Think Will Happen Next - Simply Wall St
Earnings call: Dr. Reddy's reports robust growth and strategic expansions By Investing.com - Investing.com Australia
Earnings call: Dr. Reddy's reports robust growth and strategic expansions - Investing.com India
Dr. Reddy's stock poised for recovery with new US launches and global OTC gains—BofA - Investing.com India
Dr. Reddy's stock poised for recovery with new US launches and global OTC gains—BofA By Investing.com - Investing.com South Africa
Dr Reddy's Laboratories Ltd (RDY) (HY 2025) Earnings Call Highli - GuruFocus.com
Dr. Reddy’s Labs ADR earnings missed by $0.85, revenue topped estimates - Investing.com Australia
Dr Reddy's Q2 results: Net profit falls 15% to Rs 1,255 crore - Moneycontrol
Dr Reddy’s Q2FY25 earnings preview: Expectations of steady revenue growth but margins under pressure - MSN
Dr Reddys Q2FY25 earnings preview: Expectations of steady revenue growth but margins under pressure - Zee Business
Asian Equities Traded in the US as American Depositary Receipts Climb Higher Friday - MSN
Dr Reddys Laboratories Ltd Adr Stock (RDY) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.11%
0.02%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):